Search

Your search keyword '"Regina Elena Cancer Institute"' showing total 831 results

Search Constraints

Start Over You searched for: Author "Regina Elena Cancer Institute" Remove constraint Author: "Regina Elena Cancer Institute"
831 results on '"Regina Elena Cancer Institute"'

Search Results

202. ID4: a new player in the cancer arena.

203. Persistence of HPV after radio-chemotherapy in locally advanced cervical cancer.

204. Synergistic effect of gefitinib and rofecoxib in mesothelioma cells.

205. In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy.

206. Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.

207. Transgenic mice expressing an artificial zinc finger regulator targeting an endogenous gene.

208. Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme.

209. Time to first tumor progression as outcome predictor of a second trasuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer.

210. Intracellular presence of insulin and its phosphorylated receptor in non-small cell lung cancer.

211. Methyl-CpG-binding protein 2 is phosphorylated by homeodomain-interacting protein kinase 2 and contributes to apoptosis.

212. A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes.

213. The Hippo tumor suppressor pathway: a brainstorming workshop.

214. Liposarcoma of the colon presenting as an endoluminal mass.

215. Human papillomavirus-16 E7 interacts with glutathione S-transferase P1 and enhances its role in cell survival.

216. The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis.

217. Sexual dysfunction following surgery for rectal cancer - a clinical and neurophysiological study.

218. Genetic profile identification in clinically localized prostate carcinoma.

219. Stabilization of quadruplex DNA perturbs telomere replication leading to the activation of an ATR-dependent ATM signaling pathway.

220. Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression.

221. Adjuvant electrochemotherapy in veterinary patients: a model for the planning of future therapies in humans.

222. HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA.

223. Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progression.

224. Solitary true cyst of the pancreas in adults. A report of two cases.

225. Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice.

226. HIPK2 is involved in cell proliferation and its suppression promotes growth arrest independently of DNA damage.

227. Progress and challenges in the vaccine-based treatment of head and neck cancers.

228. An E7-based therapeutic vaccine protects mice against HPV16 associated cancer.

229. p63 regulation by microRNAs.

230. Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer.

231. Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation.

232. Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade.

233. Class I HLA folding and antigen presentation in beta 2-microglobulin-defective Daudi cells.

234. Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis.

235. Novel activation domain derived from Che-1 cofactor coupled with the artificial protein Jazz drives utrophin upregulation.

236. Adenocarcinoma of the esophagogastric junction: the role of abdominal-transhiatal resection.

237. Transcriptional regulation of hypoxia-inducible factor 1alpha by HIPK2 suggests a novel mechanism to restrain tumor growth.

238. Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis.

239. Zoledronic acid for the treatment of appendicular osteosarcoma in a dog.

240. Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function.

241. Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc.

242. Electrochemotherapy for the treatment of squamous cell carcinoma in cats: a preliminary report.

243. Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients.

244. YAP: at the crossroad between transformation and tumor suppression.

245. Posttranslational regulation of NF-YA modulates NF-Y transcriptional activity.

246. Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study.

247. Detection of bovine papillomavirus type 2 in the peripheral blood of cattle with urinary bladder tumours: possible biological role.

248. Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: a mono-institutional phase II study.

249. Identification of the minimal melanocyte-specific promoter in the melanocortin receptor 1 gene.

250. G-quadruplex ligand RHPS4 potentiates the antitumor activity of camptothecins in preclinical models of solid tumors.

Catalog

Books, media, physical & digital resources